Pham, V. Luu, Christopher Meinzen, Rafael S. Arias, Noah G. Schwartz, Adi Rattner, Catherine H. Miele, Philip L. Smith, Hartmut Schneider, J. Jaime Miranda, Robert H. Gilman, Vsevolod Y. Polotsky, William Checkley, and Alan R. Schwartz. comparative cross-sectional study of sleep-disordered breathing in the original Peruvian highlands and lowlands. High Alt Med Biol. 18: 11-19, 2017.
BACKGROUND Altitude can highlight irregular sleep breathing (SDB), which has been associated with cardiovascular and metabolic diseases. SDB on the plateau is not marked in large controlled studies. The purpose of this study was to compare the prevalence and severity of SDB in the highlands and lowlands.
METHOD 170 age, body-mass Index, (BMI), and gender couples (age 58.2 ± 12.4 years, BMI 27.2 ± 3.5 kg / m2, and 86 male and 84 female) from Crónicas Cohort Study recruited at sea level (Lima) and high altitude (Puno, 3825 m) arrangements in Peru. Participants underwent nocturnal polygraph simultaneously and actigraphy to characterize patterns of breathing, movement arousals, and sleep / wake state. We compared the prevalence of SDB, type, and severity between the highlands and lowlands as measured by the apnea-hypopnea index (AHI) and pulse oximetry (SpO2) during sleep.
RESULTS Greater prevalence of sleep apnea in the highlands than in the lowlands (77% vs 54%, p <0.001). Compared with the lowlands, highlands have a two-fold increase in AHI due to the increase in the central rather than obstructive apnea. On the plateau compared with the lowlands, lower SpO2 during wakefulness and a further decrease during sleep (p <0.001). Hypoxemia during wakefulness predict sleep apnea in the highlands, and it seems to mediate the effects of altitude on the prevalence of sleep apnea. Surprisingly, hypoxemia also quite common in the lowlands, and it is also associated with an increased likelihood of sleep apnea.
CONCLUSION high altitude and hypoxemia at both high and low altitudes associated with an increased prevalence and severity of SDB. Our findings show that most of the highlands remain at risk for SDB sequelae.
Cross-Sectional Comparison of Sleep-Disordered Breathing in Native Peruvian Highlanders and Lowlanders.
Increased Cardiometabolic Risk and Worsening hypoxemia at High Altitude.
Miele, Catherine H., Alan R. Schwartz, Robert H. Gilman, Luu Pham, Robert A. Wise, Victor G. Davila-Roman, Jonathan C. June, Vsevolod Y. Polotsky, J. Jaime Miranda, Fabiola Leon-Velarde and William Checkley. Increased risk of cardiometabolic and worsening hypoxemia at high altitude. High Alt Med Biol. 17: 93-100 syndrome, 2016.-Metabolic, insulin resistance, diabetes, and dyslipidemia associated with an increased risk of cardiovascular disease.
While excessive erythrocytosis is associated with cardiovascular complications, it is not clear how the worsening hypoxemia of any level affecting cardiometabolic risk factors in a population of high altitude. We studied the relationship between lunch break oxyhemoglobin saturation and cardiometabolic risk factors in adult participants who stay in Puno, Peru (3825 m asl). We used multivariable logistic regression model to study the relationship between having a lower oxyhemoglobin saturation and cardiometabolic risk markers.
Description: A polyclonal antibody for detection of BMP-7 from Human, Mouse, Rat. This BMP-7 antibody is for WB , IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the Internal region of human BMP-7
Description: A polyclonal antibody for detection of BMP-7 from Human, Mouse, Rat. This BMP-7 antibody is for WB , IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the Internal region of human BMP-7
Description: A polyclonal antibody for detection of BMP-7 from Human, Mouse, Rat. This BMP-7 antibody is for WB , IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the Internal region of human BMP-7
Description: TGF-β family members are key modulators of cell proliferation, differentiation, matrix synthesis, and apoptosis. As implied by their name, BMPs initiate, promote, and regulate the development, growth, and remodeling of bone and cartilage. In addition to this role, BMPs are also involved in prenatal development and postnatal growth, remodeling, and maintenance of a variety of other tissues and organs. BMP-7, also known as osteogenic protein-1 or OP-1, is a potent bone inducing agent, which in the presence of an appropriate osteoconductive carrier (e.g. collagen sponge or synthetic hydroxyapatite) can be used in the treatment of bone defects. A bone-graft substitute, called OP-1TM implant, made of recombinant human BMP-7 associated with bovine bone-derived collagen, has recently been approved by the FDA as a device for treating critical-size bone fractures. The potential use of BMP-7 in dental reconstructive surgeries is currently under investigation. Recombinant Human BMP-7 is a 28.8 kDa homodimeric glycoprotein consisting of two 117 amino acid subunits, which correspond to amino acid residues 315 to 431 of the full-length BMP-7 precursor.
Description: TGF-β family members are key modulators of cell proliferation, differentiation, matrix synthesis, and apoptosis. As implied by their name, BMPs initiate, promote, and regulate the development, growth, and remodeling of bone and cartilage. In addition to this role, BMPs are also involved in prenatal development and postnatal growth, remodeling, and maintenance of a variety of other tissues and organs. BMP-7, also known as osteogenic protein-1 or OP-1, is a potent bone inducing agent, which in the presence of an appropriate osteoconductive carrier (e.g. collagen sponge or synthetic hydroxyapatite) can be used in the treatment of bone defects. A bone-graft substitute, called OP-1TM implant, made of recombinant human BMP-7 associated with bovine bone-derived collagen, has recently been approved by the FDA as a device for treating critical-size bone fractures. The potential use of BMP-7 in dental reconstructive surgeries is currently under investigation. Recombinant Human BMP-7 is a homodimeric glycoprotein consisting of two 117 amino acid subunits, which correspond to amino acid residues 315 to 431 of the full-length BMP-7 precursor. Recombinant Human BMP-7 has a calculated molecular weight of 26.4 kDa; however, due to glycosylation, the BMP-7 homodimer migrates at an apparent molecular weight of approximately 25-35 kDa by SDS-PAGE analysis under non-reducing conditions.
Description: Enzyme-linked immunosorbent assay kit for quantification of Human BMP-7 in samples from serum, plasma, tissue homogenates and other biological fluids.
Description: Enzyme-linked immunosorbent assay kit for quantification of Mouse BMP-7 in samples from serum, plasma, tissue homogenates and other biological fluids.
Description: Enzyme-linked immunosorbent assay kit for quantification of Rat BMP-7 in samples from serum, plasma, tissue homogenates and other biological fluids.
Description: Description of target: Bone morphogenetic protein 7 or BMP7 (also known as osteogenic protein-1 or OP-1) is a protein that in humans is encoded by the BMP7 gene.The protein encoded by this gene is a member of the TGF-β superfamily. Like other members of the bone morphogenetic protein family of proteins, it plays a key role in the transformation of mesenchymal cells into bone and cartilage. It is inhibited by noggin and a similar protein, chordin, which are expressed in the Spemann-Mangold Organizer. BMP7 may be involved in bone homeostasis. It is expressed in the brain, kidneys and bladder.;Species reactivity: Human;Application: ELISA;Assay info: ;Sensitivity: < 10 pg/ml
Description: Quantitativesandwich ELISA kit for measuring Human Bone morphogenetic protein 7, BMP-7 in samples from serum, plasma, cell culture supernates. A new trial version of the kit, which allows you to test the kit in your application at a reasonable price.
Human Bone morphogenetic protein 7, BMP-7 ELISA Kit
Description: Quantitativesandwich ELISA kit for measuring Human Bone morphogenetic protein 7, BMP-7 in samples from serum, plasma, cell culture supernates. Now available in a cost efficient pack of 5 plates of 96 wells each, conveniently packed along with the other reagents in 5 separate kits.
Mouse Bone morphogenetic protein 7, BMP-7 ELISA Kit
Description: Quantitativesandwich ELISA kit for measuring Mouse Bone morphogenetic protein 7, BMP-7 in samples from serum, plasma, cell culture supernates, tissue homogenates. A new trial version of the kit, which allows you to test the kit in your application at a reasonable price.
Mouse Bone morphogenetic protein 7, BMP-7 ELISA Kit
Description: Quantitativesandwich ELISA kit for measuring Mouse Bone morphogenetic protein 7, BMP-7 in samples from serum, plasma, cell culture supernates, tissue homogenates. Now available in a cost efficient pack of 5 plates of 96 wells each, conveniently packed along with the other reagents in 5 separate kits.
Mouse Bone morphogenetic protein 7,BMP-7 ELISA Kit
Description: Bone Morphogenetic Protein-7 Human Recombinant produced in E.Coli is a monomeric, non-glycosylated, polypeptide chain containing 139 amino acids and having a molecular mass of 15679.97 Dalton. ;The BMP-7 is purified by proprietary chromatographic techniques.
Description: A sandwich ELISA kit for quantitative measurement of Mouse BMP-7 (Bone Morphogenetic Protein 7) in samples from Serum, Plasma, Cell supernatant
ELISA kit for Porcine BMP-7 (Bone Morphogenetic Protein 7)
Description: A sandwich ELISA kit for quantitative measurement of Porcine BMP-7 (Bone Morphogenetic Protein 7) in samples from Serum, Plasma, Cell supernatant
ELISA kit for Rat BMP-7 (Bone Morphogenetic Protein 7)
Description: A sandwich ELISA kit for quantitative measurement of Rat BMP-7 (Bone Morphogenetic Protein 7) in samples from Serum, Plasma, Cell supernatant
CLIA kit for Human BMP-7 (Bone Morphogenetic Protein 7)
Description: A sandwich CLIA kit for quantitative measurement of Human BMP-7 (Bone Morphogenetic Protein 7) in samples from Serum, Plasma, Cell supernatant
CLIA kit for Mouse BMP-7 (Bone Morphogenetic Protein 7)
Description: A sandwich CLIA kit for quantitative measurement of Mouse BMP-7 (Bone Morphogenetic Protein 7) in samples from Serum, Plasma, Cell supernatant
CLIA kit for Rat BMP-7 (Bone Morphogenetic Protein 7)
Description: A sandwich CLIA kit for quantitative measurement of Rat BMP-7 (Bone Morphogenetic Protein 7) in samples from Serum, Plasma, Cell supernatant
ELISA kit for Human BMP-7 (Bone Morphogenetic Protein 7)
Description: A sandwich ELISA kit for quantitative measurement of Human BMP-7 (Bone Morphogenetic Protein 7) in samples from Serum, Plasma, Cell supernatant
BMP-7 Bone Morphogenetic Protein-7 Human Recombinant Protein, Plant
Description: Bone Morphogenetic Protein-7 Human Recombinant produced in Plant is a monomeric, glycosylated, polypeptide chain containing 144 amino acids and having a molecular mass of 16.5kDa, and fused to a 6xHis-tag at the N-terminus. ;The BMP-7 is purified by proprietary chromatographic techniques.
BMP-7 Bone Morphogenetic protein-7 Human Recombinant Protein, HEK
Description: BMP-7 Human Recombinant produced in HEK cells is a glycosylated disulfide-linked homodimer, having a molecular weight range of 30-38kDa due to glycosylation.;The BMP7 corresponds to amino acid residues 315 to 431 of the full-length BMP-7 precursor and is purified by proprietary chromatographic techniques.
BMP-7 Bone Morphogenetic Protein-7 Human Recombinant Protein, CHO
Description: N-TERMINAL---Human BMP-2 (Met the signal peptide and propetide contains 139 amino acid residues. The glycosylation of BMP-7 increases the molecular mass and the glycosylated proteins migrate as 25 ~ 40 kDa in SDS-PAGE under non-reducing conditions. ;BMP-7 is purified by proprietary chromatographic techniques.
Description: BMP7 Human Recombinant produced in E.Coli is a monomeric, non-glycosylated, polypeptide chain containing 148 amino acids (293-431) and having a molecular mass of 16.8 kDa. ;The BMP-7 is fused to 8 amino acid His Tag at C-terminus & purified by proprietary chromatographic techniques.
Description: Description of target: This gene encodes a member of the transforming growth factor-beta (TGF-beta) family of proteins. The encoded preproprotein is proteolytically processed to generate each subunit of the mature homodimer, which plays a role in bone, kidney and brown adipose tissue development. This protein induces ectopic bone formation and may promote fracture healing in human patients.;Species reactivity: Human;Application: ELISA;Assay info: Quantitative Colorimentric Sandwich ELISA;Sensitivity: 63 pg/mL
Nine hundred and fifty-four participants (average age 55 years, 52% men) have information available in pulse oximetry and cardiometabolic risk markers. average oxyhemoglobin saturation was 90% (interquartile range 88% -92%) and 43 (4.5%) had excessive erythrocytosis. older age, decreased lung function height-adjustable, and a higher body mass index (BMI) is associated with having ≤85% oxyhemoglobin saturation.
